Humana Inc. (NYSE:HUM) Shares Sold by Groupama Asset Managment

Groupama Asset Managment cut its holdings in Humana Inc. (NYSE:HUM - Free Report) by 75.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,358 shares of the insurance provider's stock after selling 4,233 shares during the period. Groupama Asset Managment's holdings in Humana were worth $345,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of HUM. Vanguard Group Inc. boosted its position in shares of Humana by 15.8% during the fourth quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock worth $3,254,899,000 after buying an additional 1,751,857 shares during the period. State Street Corp raised its position in Humana by 1.0% in the 3rd quarter. State Street Corp now owns 5,357,420 shares of the insurance provider's stock valued at $1,701,582,000 after purchasing an additional 53,272 shares in the last quarter. Pzena Investment Management LLC grew its position in shares of Humana by 44.0% during the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider's stock worth $915,736,000 after buying an additional 1,103,132 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Humana by 2.3% during the fourth quarter. Geode Capital Management LLC now owns 2,883,614 shares of the insurance provider's stock worth $729,658,000 after buying an additional 63,562 shares during the period. Finally, Norges Bank purchased a new position in Humana in the fourth quarter worth approximately $416,202,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Humana Stock Performance

Shares of NYSE HUM traded up $3.35 during mid-day trading on Wednesday, hitting $285.30. 2,653,232 shares of the company were exchanged, compared to its average volume of 1,743,722. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm has a market cap of $34.43 billion, a price-to-earnings ratio of 28.67, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62. The stock has a 50 day simple moving average of $265.60 and a 200-day simple moving average of $270.92. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, sell-side analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.24%. Humana's payout ratio is currently 35.58%.

Analyst Ratings Changes

A number of brokerages have commented on HUM. Barclays increased their price objective on shares of Humana from $255.00 to $270.00 and gave the company an "equal weight" rating in a research report on Thursday, February 13th. Truist Financial lifted their price target on Humana from $260.00 to $290.00 and gave the stock a "hold" rating in a report on Monday, January 6th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $283.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Morgan Stanley decreased their target price on Humana from $301.00 to $285.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 12th. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $290.00 price target on shares of Humana in a report on Wednesday, February 12th. Seventeen investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Humana presently has an average rating of "Hold" and a consensus price target of $284.25.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.